Açıklama

Study design and patient enrollment for the IBS-diarrhea symptom exacerbation cohort are outlined, detailing the collection of fecal, salivary, and dental plaque samples from participants during baseline and flare periods.

Figure 1

Flowchart

Source Paper

Omics profiles of fecal and oral microbiota change in irritable bowel syndrome patients with diarrhea and symptom exacerbation.

Journal of gastroenterology (2022)

PMID: 35908139

DOI: 10.1007/s00535-022-01888-2

Cite This Figure

![Figure 1: Study design and patient enrollment for the IBS-diarrhea symptom exacerbation cohort are outlined, detailing the collection of fecal, salivary, and dental plaque samples from participants during baseline and flare periods.]()

> Source: Yukari Tanaka et al. "Omics profiles of fecal and oral microbiota change in irritable bowel syndrome p." *Journal of gastroenterology*, 2022. PMID: [35908139](https://pubmed.ncbi.nlm.nih.gov/35908139/)

<figure>
  <img src="" alt="Study design and patient enrollment for the IBS-diarrhea symptom exacerbation cohort are outlined, detailing the collection of fecal, salivary, and dental plaque samples from participants during baseline and flare periods." />
  <figcaption>Figure 1. Study design and patient enrollment for the IBS-diarrhea symptom exacerbation cohort are outlined, detailing the collection of fecal, salivary, and dental plaque samples from participants during baseline and flare periods.<br>  Source: Yukari Tanaka et al. "Omics profiles of fecal and oral microbiota change in irritable bowel syndrome p." <em>Journal of gastroenterology</em>, 2022. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/35908139/">35908139</a></figcaption>
</figure>

İlgili Kanıtlar

L-Glutamine için Irritable Bowel Syndrome (IBS)

Derece C · 2 çalışma